This is an open, single-arm, phase I/phase II clinical study to evaluate efficacy and safety
of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Relapsed
Refractory (R/R) adult acute lymphoblastic leukemia bridging allogeneic hematopoietic stem
cell transplantation.